Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$573M |
| 2 |
Microsoft
MSFT
|
+$529M |
| 3 |
McDonald's
MCD
|
+$469M |
| 4 |
Walt Disney
DIS
|
+$303M |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$291M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$482M |
| 2 |
Comcast
CMCSA
|
+$481M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$381M |
| 4 |
Sherwin-Williams
SHW
|
+$374M |
| 5 |
CELG
Celgene Corp
CELG
|
+$341M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 56.22% |
| 2 | Technology | 7.41% |
| 3 | Consumer Discretionary | 6.04% |
| 4 | Financials | 5.89% |
| 5 | Industrials | 4.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
BBG
6776
PUT
DELISTED
Bill Barrett Corp
BBG
| $76K | ﹤0.01% |
16,800
+5,100
| +44% | +$29.7K |
2016 Q4
1 quarter
|
|
|
SNAK
6777
DELISTED
Inventure Foods, Inc.
SNAK
| $76K | ﹤0.01% |
17,199
+351
| +2% | +$2.11K |
2016 Q4
1 quarter
|
|
|
AGEN
6778
CALL
Agenus
AGEN
$377M
| $75K | ﹤0.01% |
1,014
-137
| -12% | -$10.9K |
2015 Q1
8 quarters
|
|
6779
CALL
MidCap Financial Investment
MFIC
$703M
| $75K | ﹤0.01% |
3,833
-2,267
| -37% | -$42K |
2016 Q3
2 quarters
|
|
6780
CALL
VirnetX Holding Corp
VHC
$44.5M
| $75K | ﹤0.01% |
1,630
+290
| +22% | +$13.3K |
2013 Q2
15 quarters
|
|
6781
PUT
Anavex Life Sciences
AVXL
$162M
| $74K | ﹤0.01% |
12,900
-6,000
| -32% | -$31K |
2016 Q4
1 quarter
|
|
|
BCLI
6782
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $74K | ﹤0.01% |
+1,158
| New | +$60.3K |
2017 Q1
0 quarters
|
|
|
SGMO
6783
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $74K | ﹤0.01% |
14,200
-34,400
| -71% | -$138K |
2013 Q2
15 quarters
|
|
6784
PUT
Calumet Specialty Products
CLMT
$4.88B
| $73K | ﹤0.01% |
19,100
+5,200
| +37% | +$20.6K |
2013 Q2
15 quarters
|
|
|
PLG
6785
Platinum Group Metals
PLG
$162M
| $73K | ﹤0.01% |
+4,463
| New | +$77.6K |
2017 Q1
0 quarters
|
|
6786
Verastem
VSTM
$690M
| $73K | ﹤0.01% |
+2,919
| New | +$46.4K |
2017 Q1
0 quarters
|
|
|
NH
6787
DELISTED
NantHealth, Inc
NH
| $73K | ﹤0.01% |
+980
| New | +$109K |
2017 Q1
0 quarters
|
|
|
GLBL
6788
DELISTED
TerraForm Global, Inc. Class A Common Stock
GLBL
| $73K | ﹤0.01% |
15,297
-33,355
| -69% | -$151K |
2015 Q3
6 quarters
|
|
|
OCRX
6789
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $73K | ﹤0.01% |
+55,673
| New | +$70.9K |
2017 Q1
0 quarters
|
|
6790
Lattice Semiconductor
LSCC
$19.1B
| $72K | ﹤0.01% |
+10,389
| New | +$73.4K |
2017 Q1
0 quarters
|
|
6791
Talphera
TLPH
$60.7M
| $72K | ﹤0.01% |
+1,137
| New | +$66.9K |
2017 Q1
0 quarters
|
|
6792
CALL
AXT Inc
AXTI
$5.59B
| $71K | ﹤0.01% |
+12,300
| New | +$76.4K |
2017 Q1
0 quarters
|
|
|
CBAY
6793
DELISTED
Cymabay Therapeutics
CBAY
| $71K | ﹤0.01% |
+16,404
| New | +$47.1K |
2017 Q1
0 quarters
|
|
|
ANFI
6794
PUT
DELISTED
AMIRA NATURE FOODS LTD
ANFI
| $71K | ﹤0.01% |
13,300
-300
| -2% | -$1.67K |
2015 Q1
8 quarters
|
|
|
RBPAA
6795
DELISTED
Royal Bancshares Of Pennsylvania Inc
RBPAA
| $71K | ﹤0.01% |
+18,243
| New | +$73.1K |
2017 Q1
0 quarters
|
|
|
MACK
6796
CALL
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $71K | ﹤0.01% |
2,936
-3,012
| -51% | -$75.4K |
2013 Q3
14 quarters
|
|
6797
Acacia Research
ACTG
$423M
| $70K | ﹤0.01% |
+12,115
| New | +$70.7K |
2017 Q1
0 quarters
|
|
|
6798
CALL
Lattice Semiconductor
LSCC
$19.1B
| $70K | ﹤0.01% |
+10,100
| New | +$71.4K |
2017 Q1
0 quarters
|
|
6799
Valhi
VHI
$416M
| $70K | ﹤0.01% |
1,773
-2,569
| -59% | -$104K |
2014 Q3
10 quarters
|
|
|
LGCY
6800
PUT
DELISTED
Legacy Reserves Inc. Common Stock
LGCY
| $70K | ﹤0.01% |
30,400
+3,700
| +14% | +$8.35K |
2014 Q4
9 quarters
|
|
Similar funds
Citadel Advisors's Q1 2017 Portfolio in Review
As of Q1 2017, Citadel Advisors held 8,634 positions worth $109B, up 11% from $99B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Citadel Advisors deployed $4.43B of net new capital in Q1 2017, opening 1,445 new positions and adding to 2,647 existing holdings. Its largest new stake was Meta Platforms (Facebook): 4,289,917 shares worth $609M.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, down from 63% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $482M trimmed.
- Citadel Advisors's largest Q1 2017 buy was Meta Platforms (Facebook): 4,289,917 shares worth $609M.
- Citadel Advisors added most to Microsoft in Q1 2017, an estimated $529M increase.
- Citadel Advisors's biggest Q1 2017 reduction was Alphabet (Google) Class A, cutting an estimated $482M.
- Citadel Advisors fully exited Celgene Corp in Q1 2017, selling an estimated $341M.
- Citadel Advisors's ten largest holdings make up 19% of its $109B portfolio in Q1 2017.
- Citadel Advisors opened 1,445 new positions and closed 1,267 in Q1 2017.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $109B.
Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.